The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: Results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

A. K. Burnett*, R. K. Hills, A. E. Hunter, D. Milligan, W. J. Kell, K. Wheatley, J. Yin, M. F. McMullin, H. Dignum, D. Bowen, N. H. Russell

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

120 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: Results from the LRF AML14 and NCRI AML16 pick-a-winner comparison'. Together they form a unique fingerprint.

Medicine & Life Sciences